IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.

Trial Details

NCT ID
NCT07483554
Phase
PHASE2
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • IBI343,Gemcitabine, Albumin-bound Paclitaxel
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Signed written informed consent, willing and able to comply with the protocol-specified visits and related procedures.
  • At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
  • Age ≥ 18 years, no gender restrictions.
  • An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →